![Frontiers | Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia Frontiers | Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia](https://www.frontiersin.org/files/Articles/684621/fonc-11-684621-HTML-r1/image_m/fonc-11-684621-g001.jpg)
Frontiers | Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia
![Frontiers | Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies Frontiers | Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies](https://www.frontiersin.org/files/MyHome%20Article%20Library/863177/863177_Thumb_400.jpg)
Frontiers | Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies
![Frontiers | Lymphoproliferation in Inborn Errors of Immunity: The Eye Does Not See What the Mind Does Not Know Frontiers | Lymphoproliferation in Inborn Errors of Immunity: The Eye Does Not See What the Mind Does Not Know](https://www.frontiersin.org/files/MyHome%20Article%20Library/856601/856601_Thumb_400.jpg)